莫沙必利联用胃复春胶囊治疗功能性消化不良效果分析  

Clinical effect of mosapride combined with Weifuchun capsule on functional dyspepsia

作　　者：张道铭 黄晶晶 许丽娜 ZHANG Daoming;HUANG Jingjing;XU Lina(Gastroenterology,Anhui Lujiang County Peoples Hospital,Hefei,Anhui,231500,China)

机构地区：[1]安徽庐江县人民医院消化内科,安徽合肥231500

出　　处：《中国冶金工业医学杂志》2024年第6期628-630,共3页Chinese Medical Journal of Metallurgical industry

基　　金：浙江省科技计划项目(2022C03131)。

摘　　要：目的分析莫沙必利联合胃复春胶囊治疗功能性消化不良的临床效果。方法将我院2019年3月—2020年1月收治的功能性消化不良患者116例根据随机数字表法分为对照组和观察组,每组各58例。对照组口服莫沙必利治疗,观察组在对照组基础上联合胃复春胶囊治疗,疗程均为2个月。比较两组的临床疗效、中医症状评分、血清胃蛋白酶原及免疫功能水平、不良反应情况。结果观察组的总有效率及痊显率均优于对照组(χ^(2)=9.265、7.315,均P<0.05);观察组治疗后各中医症状评分均高于对照组,胃蛋白酶原、CD_(4)^(+)T淋巴细胞(CD_(4)^(+)T)、CD_(8)^(+)T淋巴细胞(CD_(8)^(+)T)、CD_(4)^(+)T/CD_(8)^(+)T均优于对照组,组间比较差异显著(t=9.37、7.54、8.51、8.34、5.68、4.75、8.71、5.34、6.23、7.76,均P<0.05);两组不良反应比较无显著差异(P>0.05)。结论莫沙必利联合胃复春胶囊治疗功能性消化不良的临床疗效显著,可增强胃蛋白酶原分泌,调节免疫功能,且应用安全性高。Objective To analyze the clinical efficacy of mosapride combined with Weifuchun capsules in the treatment of functional dyspepsia.Methods A total of 116 patients with functional dyspepsia treated in our hospital from March 2019 to January 2020 were randomly divided into a control group and an observation group,with 58 cases in each group.The control group was treated with oral mosapride,while the observation group received additional treatment with Weifuchun capsules on the basis of the control group,with both groups undergoing a 2-month treatment course.The clinical efficacy,Traditional Chinese Medicine(TCM)symptom scores,levels of serum pepsinogen,immune function,and incidence of adverse reactions were compared between the two groups.Results The total effective rate and cure rate in the observation group were significantly higher than those in the control group(χ^(2)=9.265,7.315,both P<0.05).Post-treatment TCM symptom scores,levels of pepsinogen,CD_(4)^(+)T lymphocytes,CD_(8)^(+)T lymphocytes,and the CD_(4)^(+)/CD_(8)^(+)ratio in the observation group were significantly better than those in the control group,with statistically significant differences between the groups(t=9.37,7.54,8.51,8.34,5.68,4.75,8.71,5.34,6.23,7.76,all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of mosapride and Weifuchun capsules has a significant clinical effect in treating functional dyspepsia,enhancing pepsinogen secretion,and regulating immune function,with a high safety profile.

关 键 词：胃复春胶囊 功能性消化不良 莫沙必利 胃蛋白酶原 免疫功能 

分 类 号：R573[医药卫生—消化系统]